Prevalence and associated risk factors of gout among patients at Khyber Teaching Hospital Peshawar: A cross-sectional study
DOI:
https://doi.org/10.70347/svsthya.v1i3.72Keywords:
Gout, hyperuricemia, uric acid, metabolic disease, comorbidity, noncommunicable diseasesAbstract
Hyperuricemia and gout represent significant global public health challenges with varying prevalence rates across populations. This study aimed to investigate the prevalence and associated risk factors for gout among patients at the Khyber Teaching Hospital, Peshawar, Pakistan. This cross-sectional analytical study was conducted from January to March 2024 and involved 100 patients (57% female, 43% male) aged 18–65 years. Participants were recruited via systematic random sampling from the orthopedic department. Data collection included demographic information, anthropometric measurements, medical history, and serum uric acid levels, which were analyzed via the uricase enzymatic colorimetric method. 93% of the patients were between 21 and 60 years old, with 54% reporting a family history of gout. Notably, 95% of the participants presented elevated uric acid levels (>6.8 mg/dL in men, >6.0 mg/dL in women), with 40% falling within the 7.1–8.0 mg/dL range. The major comorbidities included hypertension (72%), thyroid problems (45%), and kidney disease (34%). Protein-rich diet consumption was reported by 84% of the participants, whereas alcohol consumption was reported by 17%. The general health assessment classified 65% of the participants as unhealthy. The findings indicate a greater prevalence of gout among females in this population, contradicting traditional patterns, along with significant associations with comorbidities and dietary factors. This study highlights the need for sex-specific screening protocols and comprehensive management approaches that address both primary gout symptoms and associated conditions. These results emphasize the importance of early intervention and lifestyle modification strategies in gout management within the South Asian.
Downloads
References
Ahn JK. Epidemiology and treatment-related concerns of gout and hyperuricemia in Korean. Journal of Rheumatic Diseases 2023;30:88–98. https://doi.org/10.4078/jrd.2022.0001.
Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol 2020;16:380–90. https://doi.org/10.1038/s41584-020-0441-1.
Bardin T, Magnat E, Clerson P, Richette P, Rouchon B. Epidemiology of gout and hyperuricemia in New Caledonia. Joint Bone Spine 2022;89:105286. https://doi.org/10.1016/j.jbspin.2021.105286.
McCormick N, Rai SK, Lu N, Yokose C, Curhan GC, Choi HK. Estimation of primary prevention of gout in men through modification of obesity and other key lifestyle factors. JAMA Netw Open 2020;3:e2027421. https://doi.org/10.1001/jamanetworkopen.2020.27421.
Litwin M, Michałkiewicz J, Niemirska A, Gockowska L, Kubiszewska I, Wierzbicka A, et al. Inflammatory activation in children with primary hypertension. Pediatr Nephrol 2010;25:1711–8. https://doi.org/10.1007/s00467-010-1548-4.
Kim JH, Lim JS. The association between C-reactive protein, metabolic syndrome, and prediabetes in Korean children and adolescents. Ann Pediatr Endocrinol Metab 2022;27:273–80. https://doi.org/10.6065/apem.2142226.113.
Pan J, Cai X, Chen J, Xu M, Hu J, Mao Y, et al. Association Between high-sensitivity C-reactive protein trajectories and the incidence of metabolic syndrome:A retrospective cohort study. J Inflamm Res 2024;17:8501–11. https://doi.org/10.2147/JIR.S493111.
Han T, Chen W, Qiu X, Wang W. Epidemiology of gout – Global burden of disease research from 1990 to 2019 and future trend predictions. Ther Adv Endocrinol Metab 2024;15:27295. https://doi.org/10.1177/20420188241227295.
Han Q-X, Zhang D, Zhao Y-L, Liu L, Li J, Zhang F, et al. Risk factors for hyperuricemia in chinese centenarians and near-centenarians. Clin Interv Aging 2019;14:2239–47. https://doi.org/10.2147/CIA.S223048.
Guan S, Tang Z, Fang X, Wu X, Liu H, Wang C, et al. Prevalence of hyperuricemia among Beijing post-menopausal women in 10 years. Arch Gerontol Geriatr 2016;64:162–6. https://doi.org/10.1016/j.archger.2016.02.002.
Huang J, Ma ZF, Zhang Y, Wan Z, Li Y, Zhou H, et al. Geographical distribution of hyperuricemia in mainland China: a comprehensive systematic review and meta-analysis. Glob Health Res Policy 2020;5:52. https://doi.org/10.1186/s41256-020-00178-9.
Latourte A, Dumurgier J, Paquet C, Richette P. Hyperuricemia, Gout, and the Brain—an Update. Curr Rheumatol Rep 2021;23:82. https://doi.org/10.1007/s11926-021-01050-6.
Sumpter NA, Saag KG, Reynolds RJ, Merriman TR. Comorbidities in gout and hyperuricemia: causality or epiphenomena? Curr Opin Rheumatol 2020;32:126–33. https://doi.org/10.1097/BOR.0000000000000691.
Zhong L, Liu S, Qiu X, Zeng X, Su L, Huang D, et al. High Prevalence of Hyperuricemia and Associated Factors among Zhuang Adults: A Cross-Sectional Study Based on the Ethnic Minority Population Cohort in the Southwestern China. Int J Environ Res Public Health 2022;19:16040. https://doi.org/10.3390/ijerph192316040.
Zhang M, Zhu X, Wu J, Huang Z, Zhao Z, Zhang X, et al. Prevalence of Hyperuricemia Among Chinese Adults: Findings From Two Nationally Representative Cross-Sectional Surveys in 2015–16 and 2018–19. Front Immunol 2022;12:791983. https://doi.org/10.3389/fimmu.2021.791983.
Song J, Jin C, Shan Z, Teng W, Li J. Prevalence and risk factors of hyperuricemia and gout: a cross-sectional survey from 31 provinces in mainland China. J Transl Int Med 2022;10:134–45. https://doi.org/10.2478/jtim-2022-0031.
Zhu Y, Pandya BJ, Choi HK. Comorbidities of Gout and Hyperuricemia in the US General Population: NHANES 2007-2008. Am J Med 2012;125:679–87. https://doi.org/10.1016/j.amjmed.2011.09.033.
Zitt E, Fischer A, Lhotta K, Concin H, Nagel G. Sex and age-specific variations, temporal trends and metabolic determinants of serum uric acid concentrations in a large population-based Austrian cohort. Sci Rep 2020;10:7578. https://doi.org/10.1038/s41598-020-64587-z.
Tao M, Ma X, Pi X, Shi Y, Tang L, Hu Y, et al. Prevalence and related factors of hyperuricaemia in Shanghai adult women of different ages: a multicentre and cross-sectional study. BMJ Open 2021;11:e048405. https://doi.org/10.1136/bmjopen-2020-048405.
Shih Y-L, Lin Y, Chen J-Y. The Association between High-Sensitivity C-Reactive Protein and Metabolic Syndrome in an Elderly Population Aged 50 and Older in a Community Receiving Primary Health Care in Taiwan. Int J Environ Res Public Health 2022;19:13111. https://doi.org/10.3390/ijerph192013111.
Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med 2017;15:123. https://doi.org/10.1186/s12916-017-0890-9.
Cicero AFG, Fogacci F, Kuwabara M, Borghi C. Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update. Medicina (B Aires) 2021;57:58. https://doi.org/10.3390/medicina57010058.
Pathmanathan K, Robinson PC, Hill CL, Keen HI. The prevalence of gout and hyperuricaemia in Australia: An updated systematic review. Semin Arthritis Rheum 2021;51:121–8. https://doi.org/10.1016/j.semarthrit.2020.12.001.
Du L, Zong Y, Li H, Wang Q, Xie L, Yang B, et al. Hyperuricemia and its related diseases: mechanisms and advances in therapy. Signal Transduct Target Ther 2024;9:212. https://doi.org/10.1038/s41392-024-01916-y.
Reynolds RJ, Irvin MR, Bridges SL, Kim H, Merriman TR, Arnett DK, et al. Genetic correlations between traits associated with hyperuricemia, gout, and comorbidities. European Journal of Human Genetics 2021;29:1438–45. https://doi.org/10.1038/s41431-021-00830-z.
Benn CL, Dua P, Gurrell R, Loudon P, Pike A, Storer RI, et al. Physiology of Hyperuricemia and Urate-Lowering Treatments. Front Med (Lausanne) 2018;5:160. https://doi.org/10.3389/fmed.2018.00160.
Butler F, Alghubayshi A, Roman Y. The Epidemiology and Genetics of Hyperuricemia and Gout across Major Racial Groups: A Literature Review and Population Genetics Secondary Database Analysis. J Pers Med 2021;11:231. https://doi.org/10.3390/jpm11030231.
Alwi J, Sari MP, Adnyana IMDM, Rustam MuhZA, Rahayu D, Irma, et al. Metode Penelitian Epidemiologi. 1st ed. Bandung: CV Media Sains Indonesia; 2023.
Adnyana IMDM. Populasi dan Sampel. In: Darwin M, editor. Metode Penelitian Pendekatan Kuantitatif. 1st ed., Bandung: CV. Media Sains Indonesia; 2021, p. 103–16.
Paulus AY, Sulaeman, Mayasari AC, Ayu JD, Musniati N, Sari MP, et al. Biostatistika Epidemiologi. 1st ed. Bandung: CV. Media Sains Indonesia; 2023.
Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. The Lancet 2021;397:1843–55. https://doi.org/10.1016/S0140-6736(21)00569-9.
Madyaningrum E, Kusumaningrum FM, Wardani RK, Susilaningrum AR, Ramadhani A. Community gout management program needed for adult people in the rural area. Journal of Community Empowerment for Health 2021;4:125. https://doi.org/10.22146/jcoemph.61591.
Singh JA, Gaffo A. Gout epidemiology and comorbidities. Semin Arthritis Rheum 2020;50:S11–6. https://doi.org/10.1016/j.semarthrit.2020.04.008.
Pathmanathan K, Robinson PC, Hill CL, Keen HI. The prevalence of gout and hyperuricaemia in Australia: An updated systematic review. Semin Arthritis Rheum 2021;51:121–8. https://doi.org/10.1016/j.semarthrit.2020.12.001.
Li Q, Li X, Wang J, Liu H, Kwong JS-W, Chen H, et al. Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements. BMJ Open 2019;9:e026677. https://doi.org/10.1136/bmjopen-2018-026677.
Kim KY, Ralph Schumacher H, Hunsche E, Wertheimer AI, Kong SX. A literature review of the epidemiology and treatment of acute gout. Clin Ther 2003;25:1593–617. https://doi.org/10.1016/S0149-2918(03)80158-3.
Song P, Wang H, Xia W, Chang X, Wang M, An L. Prevalence and correlates of hyperuricemia in the middle-aged and older adults in China. Sci Rep 2018;8:4314. https://doi.org/10.1038/s41598-018-22570-9.
Zhang Q, Gong H, Lin C, Liu Q, Baima Y, Wang Y, et al. The prevalence of gout and hyperuricemia in middle-aged and elderly people in Tibet Autonomous Region, China. Medicine 2020;99:e18542. https://doi.org/10.1097/MD.0000000000018542.
Krishnan E, Sokolove J. Uric acid in heart disease: a new C-reactive protein? Curr Opin Rheumatol 2011;23:174–7. https://doi.org/10.1097/BOR.0b013e3283432dd3.
Afinogenova Y, Danve A, Neogi T. Update on gout management: what is old and what is new. Curr Opin Rheumatol 2022;34:118–24. https://doi.org/10.1097/BOR.0000000000000861.
Al-Meshaweh AF, Jafar Y, Asem M, Akanji AO. Determinants of Blood Uric Acid Levels in a Dyslipidemic Arab Population. Med Princ Pract 2012;21:209–16. https://doi.org/10.1159/000333483.
Pathmanathan K, Robinson PC, Hill CL, Keen HI. The prevalence of gout and hyperuricaemia in Australia: An updated systematic review. Semin Arthritis Rheum 2021;51:121–8. https://doi.org/10.1016/j.semarthrit.2020.12.001.
Waksman R, Merdler I, Case BC, Waksman O, Porto I. Targeting inflammation in atherosclerosis: overview, strategy and directions. EuroIntervention 2024;20:32–44. https://doi.org/10.4244/EIJ-D-23-00606.
Wei T, Liu J, Zhang D, Wang X, Li G, Ma R, et al. The Relationship Between Nutrition and Atherosclerosis. Front Bioeng Biotechnol 2021;9:635504. https://doi.org/10.3389/fbioe.2021.635504.
Quilis N, Sivera F, Seoane-Mato D, Pérez-Ruiz F, Sánchez-Piedra C, Díaz-González F, et al. Prevalence of gout in the adult general population in Spain: Estimating the proportion of undiagnosed cases. Joint Bone Spine 2022;89:105257. https://doi.org/10.1016/j.jbspin.2021.105257.
Wijnands JMA, Viechtbauer W, Thevissen K, Arts ICW, Dagnelie PC, Stehouwer CDA, et al. Determinants of the prevalence of gout in the general population: a systematic review and meta-regression. Eur J Epidemiol 2015;30:19–33. https://doi.org/10.1007/s10654-014-9927-y.
Ratkovic N, Pandrc M, Peric V, Stojanovic M, Rancic N. Relationship between plasma high-sensitivity C-reactive protein and traditional cardiovascular risk factors among active-duty military personnel in the Republic of Serbia. Vojnosanit Pregl 2022;79:714–23. https://doi.org/10.2298/VSP210122030R.
Lu X, Li X, Zhao Y, Zheng Z, Guan S, Chan P. Contemporary epidemiology of gout and hyperuricemia in community elderly in Beijing. Int J Rheum Dis 2014;17:400–7. https://doi.org/10.1111/1756-185X.12156.
Liu R, Han C, Wu D, Xia X, Gu J, Guan H, et al. Prevalence of hyperuricemia and gout in mainland china from 2000 to 2014: a systematic review and meta-analysis. Biomed Res Int 2015;2015:1–12. https://doi.org/10.1155/2015/762820.
Tsoi MF, Chung MH, Cheung BMY, Lau CS, Cheung TT. Epidemiology of gout in Hong Kong: a population-based study from 2006 to 2016. Arthritis Res Ther 2020;22:204. https://doi.org/10.1186/s13075-020-02299-5.
Yokose C, McCormick N, Lu N, Tanikella S, Lin K, Joshi AD, et al. Trends in Prevalence of Gout Among US Asian Adults, 2011-2018. JAMA Netw Open 2023;6:e239501. https://doi.org/10.1001/jamanetworkopen.2023.9501.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Inam Ullah Khan, Moheb Ullah Khan, Shameem Khan, Ahmad Ullah, Muhammad Waqas Khan, Wahid Ullah (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This license enables reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.
